Acquisition opportunity SentrX Animal Care has recently been acquired by Dômes Pharma (Aug–Sep 2023), suggesting potential alignment opportunities with a larger distribution and manufacturing network to scale product reach and co-development of ophthalmology or crosslinked hyaluronic acid products.

Manufacturing growth Expansion in Salt Lake City with a 22,000 square foot facility (opened 2021) indicates capacity to support higher-volume production, enabling partnerships for contract manufacturing, white-labeling, or OEM collaborations.

Global distribution Past partnerships with Provet in Australia and Vet Candy collaborations show openness to distributor and education-based channels; there is room to pursue veterinary ophthalmology product distribution and training programs in additional markets.

Product focus BioHAnce crosslinked hyaluronic acid products and ocular bandage gel collaborations point to a niche in ophthalmology and biomaterials; sales opportunities exist with clinics and animal hospitals seeking advanced wound care and ocular support solutions.

Revenue potential Current revenue under $1M with strategic corporate backing from an acquirer suggests room for upsell of premium biomaterial formulations, expanded regional sales teams, and bundled offerings to mid-sized veterinary practices.